Indian entrepreneur Deepinder Goyal, founder and CEO of Eternal Ltd., the parent company of Zomato and Blinkit, has announced a personal investment of $25 million into his long-standing science initiative, Continue Research.
The venture, which he launched about two years ago, aims to extend healthy human function and life span through open-source biological research.
The move represents a significant escalation in Goyal’s commitment to scientific exploration beyond his technology and consumer businesses.
In a public post on X (formerly Twitter), Goyal revealed that the investment is “entirely personally backed” and intended to fund researchers across the world who are willing to “ask simpler questions than anyone else” about the science of biology and aging.
He said the broader vision is to lengthen the healthy portion of human life so that people “stop making short-term decisions,” arguing that much of humanity’s short-sightedness stems from the brevity of life itself.
Continue Research operates independently of Eternal and is neither a conventional company nor a commercial startup.
Instead, it functions as a hybrid of a research organization and a seed-funding entity. Its core mission is to support fundamental, open-source biological research rather than proprietary product development.
The group’s approach, according to Goyal, relies on a “systems-level understanding” of biology—studying interconnected mechanisms rather than isolated molecular events—to identify key leverage points in human aging that may have been overlooked by traditional research frameworks.
While best known for building Zomato and Blinkit into major consumer platforms, Goyal has increasingly shifted his focus toward the long-term future of human health and science.
His personal investment underscores both his financial capacity and philosophical interest in areas beyond food technology, including what he calls “humanity’s journey of conscious evolution.”
He described Continue Research as a “multi-decadal journey” meant to catalyze breakthroughs in longevity and health-span extension and to help usher humanity into a “post-Darwin era.”
The announcement comes amid a global surge of interest and capital flowing into longevity research, with scientists and investors alike focusing on understanding the molecular basis of aging, tissue repair, and lifespan extension.
Goyal’s initiative is one of the few large-scale, privately funded longevity efforts to emerge from India, positioning the country to play a larger role in this rapidly expanding field.
Goyal also hinted that the team at Continue Research has identified what he called a “penny-drop insight” about human aging—an early but potentially transformative concept that may redefine biological understanding.
He said details of the discovery would be shared in the coming weeks as the group formalizes its research collaborations and opens funding rounds for early-stage scientific teams.
By pledging $25 million of his personal wealth to Continue Research, Deepinder Goyal has placed himself among a growing cohort of global technology founders who are investing heavily in the science of longevity.
His approach—open, research-driven, and long-term—suggests that India’s entrepreneurial class may soon play a more active role in shaping the future of human health and lifespan innovation.
Also Read: Blackstone Backs Federal Bank With Nearly ₹6,200 Crore Investment